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OBJECTIVES We sought to determine whether abnormal myocardial blood flow (MBF) responses to the
cold pressor test (CPT) in patients with various risk factors may involve different mechanisms
that could lead to varying responses of short- and long-term administration of antioxidants.
BACKGROUND There is a growing body of evidence that increased vascular production of reactive oxygen
species markedly reduces the bioavailability of endothelium-derived nitric oxide, leading to
impaired vasodilator function. It is unknown whether increased oxidative stress is the
prevalent mechanism underlying endothelial dysfunction in patients with different coronary
risk factors.
METHODS Fifty patients with normal coronary angiograms were studied. The MBF responses to CPT
was determined by means of positron emission tomography before and after intravenous
infusion of 3 g vitamin C or saline (placebo), as well as after 3 months and 2 years of 2 g
vitamin C or placebo supplementation daily.
RESULTS In hypertensive patients, the change in MBF (MBF) was not modified significantly by
short-term vitamin C administration challenges (0.20  0.20 ml/g/min; p  NS) but was
significantly increased after three months and two years of treatment with vitamin C versus
baseline (0.58  0.27 and 0.63  0.17 vs. 0.14  0.18 ml/g/min; both p  0.001). In
smokers, MBF in response to CPT was significantly increased after short-term vitamin C
infusion and long-term vitamin C treatment (0.52  0.10, 0.54  0.13, 0.50  0.07 vs.
0.08  0.10 ml/g/min; all p  0.001). In hypercholesterolemic patients, no improvement
in MBF during CPT was observed after short- and long-term vitamin C treatment (0.05
0.14, 0.08  0.18, 0.02  0.19 vs. 0.08  0.16 ml/g/min; p  NS). The CPT-induced
MBF in hypertensive patients and smokers after follow-up was significant as compared with
placebo and control subjects (p  0.001).
CONCLUSIONS The present study revealed marked heterogeneous responses in MBF changes to short- and
long-term vitamin C treatment in patients with various risk factors, which highlights the
quite complex nature underlying abnormal coronary vasomotion. (J Am Coll Cardiol 2003;
42:814–22) © 2003 by the American College of Cardiology Foundation
The vascular endothelium plays a crucial role in the regu-
lation of vasomotor tone and function by synthesizing and
releasing a variety of substances (1). These include vasocon-
stricting and vasodilating factors, whereby endothelium-
derived relaxing factors, such as prostacycline, hyperpolar-
izing relaxing factor, and, most importantly, nitric oxide
(NO) (1) have been identified. Although the mechanism
underlying abnormal endothelial-dependent vascular tone is
likely to be multifactorial, there is a growing body of
evidence that increased vascular production of reactive
oxygen species (ROS) derived from enzymes, such as
nicotinamide-adenine-dinucleotide phosphate oxidase, xan-
thine oxidase, and uncoupled endothelial nitric oxide syn-
thase (eNOS), markedly reduces the bioavailability of
endothelium-derived NO, leading to impaired vasodilator
function (1–3). Until recently, the evaluation of endothelial-
dependent coronary vasomotion in humans focused primar-
ily on the intracoronary administration of acetylcholine,
bradykinin, or substance P (4). Importantly, recent studies
have demonstrated that abnormal endothelial-dependent
vasoreactivity of conduit and resistance vessels in response to
acetylcholine reveals a significant disparity (5,6). Whether
this may also apply to a physiologically more relevant
endothelial function test, such as flow-dependent dilation
and sympathetic activation by cold pressor testing (CPT),
remains to be determined (1,6).
Accordingly, the aims of this study were to: 1) assess the
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relationship between endothelial function of epicardial con-
ductance and resistance vessels in response to flow-
dependent dilation and CPT, respectively; and 2) examine
whether CPT-induced changes in myocardial blood flow
(MBF) may respond differently to short- and long-term
treatment with antioxidants.
METHODS
Study population and design. Fifty patients (29 men and
21 women; mean age 59  3 years) without angiographic
evidence of coronary artery disease were studied. We in-
cluded 20 hypertensive patients (systolic blood pressure
145 mm Hg), 10 chronic smokers (32  9 pack-years),
and 10 hypercholesterolemic patients (total serum choles-
terol 263  10 mg/dl, low-density lipoprotein [LDL]
cholesterol 168  8 mg/dl, and high-density lipoprotein
[HDL] cholesterol 46  5 mg/dl). Ten patients without
coronary risk factors served as the control group.
Quantitative coronary angiographic evaluation at baseline
and during CPT to establish flow-mediated vasoreactivity
of epicardial coronary artery was performed as described (7)
(Fig. 1). Follow-up with respect to MBF changes in
response to CPT were assessed noninvasively by dynamic
positron emission tomography (PET) after three months
and two years of follow-up. Hypertensive patients were
randomized into a placebo (n  8) and vitamin C group (n
 12), whereas chronic smokers, hypercholesterolemic pa-
tients, and control subjects were assigned to an open-label
treatment with 2 g vitamin C daily during 2-year follow-up
(Fig. 1).
Exclusion criteria included a history of unstable angina
pectoris, previous myocardial infarction, malignant hyper-
tension, diabetes mellitus, evidence of glucose intolerance,
cardiac autonomic neuropathy, valvular heart disease, pe-
ripheral vascular disease, and significant endocrine, hepatic,
renal, and inflammatory disease, as well as a regular dietary
intake of antioxidants. Only patients not on vasoactive
medication, such as angiotensin-converting enzyme inhibi-
tors, calcium channel blockers, or statins at baseline and/or
throughout the study period of two years, were recruited. In
hypertensive patients, a regular intake of diuretics and
beta-blockers was allowed for blood pressure control. Each
hypertensive patient treated with beta-blockers discontin-
ued the medication seven days before each study. In addi-
tion, during this period, patients were asked to use a
short-term calcium antagonist to control high blood pres-
sure. In these patients, study sessions were only performed if
patients did not use a short-acting calcium antagonist for at
least 24 h before the investigation. Hypercholesterolemic
patients were included in the study if they were not
receiving statin therapy at baseline and throughout the
follow-up period. During the study period, however, pa-
tients were free to begin statin medication, and, if so, they
were not considered for the follow-up evaluation. Labora-
tory analysis included total cholesterol, HDL and LDL
cholesterol, very-LDL cholesterol, triglycerides, glucose (8),
and plasma vitamin C levels (9). The dose of vitamin C was
chosen in view of previous studies (10). All patients under-
went echocardiographic studies to evaluate the left ventric-
ular mass index and left ventricular ejection fraction evalu-
ation at baseline and after two-year follow-up. The study
was approved by the local ethics committee of the University
of Freiburg, and written, informed consent was obtained
from all patients.
Quantitative coronary angiography. Coronary angiogra-
phy was performed using a biplane, isocentric, multidirec-
tional digital angiographic system (Siemens BICOR-
HICOR, Erlangen, Germany). End-diastolic images of
coronary arteries were evaluated quantitatively with auto-
matic contour detection, as described previously (7). In all
50 patients with normal coronary angiograms, as indicated
Abbreviations and Acronyms
ANOVA  analysis of variance
CPT  cold pressor test(ing)
CVR  coronary vascular resistance
eNOS  endothelial nitric oxide synthase
LAD  left anterior descending coronary artery
LCx  left circumflex artery
LDL  low-density lipoprotein
HDL  high-density lipoprotein
MBF  myocardial blood flow
NO  nitric oxide
PET  positron emission tomography
ROS  reactive oxygen species
RPP  rate-pressure product
Figure 1. Study protocol. CPT  cold pressor test; MBF  myocardial blood flow; PET  positron emission tomography; VC  vitamin C.
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by a smooth coronary vessel appearance without evidence of
lumen wall irregularities or diffuse-caliber reduction and
stenosis, quantitative measurements were performed biplane
in a selected, distinct 4- to 8-mm-long, relatively straight
proximal left anterior descending coronary artery (LAD)
segment (n  21) or left circumflex coronary artery (LCx)
segment (n  29).
Noninvasive quantification of MBF. Myocardial blood
flow was measured noninvasively by using intravenous
nitrogen-13 (13N)-labeled ammonia serial image acquisition
with dynamic PET (951 ECAT-HR, Siemens) and a
two-compartment tracer kinetic model, as described (11).
The relative myocardial perfusion was assessed visually on
re-orientated, static 13N-ammonia images, and regional
MBF was quantified from the regions of interest positioned
on three mid-ventricular slices of the left ventricle corre-
sponding to the vascular territories of the LAD, LCx, and
right coronary artery (11). The regional MBF values were
averaged to calculate mean MBF (11).
Study protocol. The PET study protocol consisted of three
study sessions. First, MBF was measured at rest. After
immersion of the left hand into ice water for 60 s, 13N-
ammonia was re-injected and CPT was continued for 60 s.
The same procedure was performed after intravenous infu-
sion of 3 g vitamin C or 100 ml 0.9% saline in the placebo
group. Beginning with intravenous 13N-ammonia adminis-
tration (15 to 20 mCi), serial transaxial emission images
were acquired (12 images per frame of 10 s each, 2 frames
of 30 s each, and 1 frame of 900 s), and time-activity curves
from the first 12 dynamic frames (12 for 10 s) were used to
calculate mean MBF. The image acquisition sequence used
for the baseline study was repeated while the CPT was
maintained for 2 min to permit trapping of 13N-ammonia in
the myocardium (11). In all patients studied, visual inspec-
tion and polar map analysis of the 13N-ammonia distribu-
tion at rest and during CPT revealed homogeneous tracer
uptake. No perfusion defects were identified.
Subsequent MBF assessments on the second session after
three months and on the third session after two years,
administration of 13N-labeled ammonia, image acquisition,
and quantification of regional MBF were performed at rest
and during CPT with previously defined regions of interest
that were identical to those in the first session. In contrast,
the short-term effect of vitamin C or saline on MBF
responses to CPT was not determined again. Regional
MBF was averaged to calculate mean MBF by two inde-
pendent investigators unaware of the patients’ assignment to
vitamin C or placebo. In each study session, heart rate,
blood pressure, and a 12-lead electrocardiogram were re-
corded continuously. From the average of heart rate and
blood pressure during the first 2 min of each image
acquisition, the rate-pressure product (RPP) was deter-
mined as an index of cardiac work. An index of coronary
vascular resistance (CVR) was calculated from the ratio of
mean arterial blood pressure (mm Hg) to MBF (ml/g/min).
Finally, the averaged mean MBF of the left ventricle was
given and was not specifically derived for the coronary
territory of the coronary artery segment for which measure-
ments of the lumen area and its changes during CPT were
obtained.
Statistical analysis. For descriptive purposes, all data are
presented as the mean value  SD and relative frequencies,
as indicated. Absolute changes of CPT-induced vascular
responses before and after vitamin C infusion or placebo
within each group were analyzed using the Wilcoxon
sign-rank test. A comparison of these changes between the
different study groups was done by two-way analysis of
variance (ANOVA) followed by the Scheffe´ F test. Corre-
lations between selected variables were estimated by Spear-
man correlation coefficients. All test procedures were two-
sided with a p value 0.05, indicating statistical
significance.
RESULTS
Clinical characteristics. The clinical characteristics of the
study groups are given in Table 1. In hypercholesterolemic
patients, total and LDL cholesterol levels were significantly
higher than in control subjects (p  0.05 by ANOVA).
After the follow-up periods of three months and two years,
the study group laboratory results were not significantly
different from baseline (p  NS by the Wilcoxon test). At
the end of two-year follow-up, a questionnaire study re-
vealed that the patients did not change their habits with
respect to diet or exercise, and none of the smokers stopped
or refrained from smoking. Regarding study co-medication,
apart from diuretics in the group of hypertensive patients
and placebo, three patients received combined therapy with
beta-blockers. In the hypercholesterolemic group, two pa-
tients decided to start with statin medication and therefore
were not considered for the follow-up evaluation.
Reproducibility of hemodynamic response to CPT. At
the baseline investigation, on both study days of coronary
angiography and PET, CPT induced comparable percent
changes in RPP (31  15% vs. 28  12%, p  0.12 by the
Wilcoxon test), implying a comparable hemodynamic effect.
Table 2 summarizes the hemodynamic measurements ob-
tained during MBF assessment with PET at baseline and
after two-year follow-up. At baseline, systolic blood pres-
sure in hypertensive patients (hypertension and placebo
groups) and RPP were significantly higher than in chronic
smokers, hypercholesterolemic patients, and control subjects
(p  0.05 by ANOVA) (Table 2). In all protocols, CPT
induced a significant increase in heart rate, systolic and
diastolic blood pressure, and RPP, owing to sympathetic
activation (p  0.05 by the Wilcoxon test). However, the
overall mean RPPs at rest and during CPT at baseline and
two-year follow-up were not significantly different (p 
0.17 and 0.98, respectively). In addition, there was a close
correlation between the resting RPP and RPP during CPT
obtained at baseline and the two-year time point (r  0.93
and 0.90, respectively; p  0.0001), indicating that the
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hemodynamic changes to CPT on repeated assessments
were relatively consistent and reproducible. Lastly, the
CPT-induced percent change of RPP determined at base-
line and during the follow-up period did not differ signifi-
cantly within the study population (28  12% vs. 25  8%;
p  0.22), indicating comparable myocardial work load for
repeated hemodynamic assessments.
Responses of epicardial arteries to CPT. Table 3 depicts
the responses of the epicardial lumen area to CPT in each
study group. The baseline values of the mean lumen area did
not differ significantly between the different study groups (p
 NS by ANOVA). However, the mean lumen area of the
epicardial coronary artery was significantly reduced from 6.0
 0.5 to 5.3  0.5 mm2 (p  0.001) in hypertensive
patients compared with control subjects. Furthermore, there
was a nonsignificant decrease of the mean lumen area from
4.6 0.4 to 4.3 0.4 mm2 (p NS) in the placebo group.
In smokers and hypercholesterolemic patients, CPT led to a
significant decrease of the mean lumen area from 6.2  0.8
to 4.2  0.5 mm2 and from 5.1  0.4 to 4.3  0.3 mm2,
respectively (p  0.002). In contrast, in control subjects
CPT induced an increase of the mean lumen area from 4.7
 0.5 to 5.8  0.6 mm2 (p  0.002). The group
comparison of a CPT-induced decrease of the mean lumen
area in the groups of patients with various coronary risk
factors was significant when compared with a blood flow-
mediated increase of the mean lumen area in control
subjects (p  0.03 by ANOVA).
Responses of MBF and CVR to CPT. Responses of
MBF and CVR at baseline and two years follow-up for
different groups are depicted in Table 4. In addition, the
percent changes of MBF in response to CPT during
repeated assessment of hypertensive and hypercholester-
olemic patients and in smokers are summarized in Figure 2.
At baseline, MBF measured by dynamic PET during CPT
revealed a markedly reduced increase of MBF in hyperten-
sive and hypercholesterolemic patients, as well as in chronic
smokers, compared with the control group (p  0.001 by
ANOVA) (Table 4, Fig. 2). Short-term administration of
vitamin C did not augment CPT-induced increases in MBF
in hypertensive patients (p  NS) (Table 4, Fig. 2). Three
months and two years of vitamin C treatment, however,
resulted in a significant improvement of MBF in response to
CPT (p 0.001) (Table 4, Fig. 2). As expected, placebo did
not modify CPT-induced changes in MBF compared withTa
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Table 2. Responses of Epicardial Lumen Area to CPT
Baseline
(mm2)
CPT
(mm2)
Hypertensive patients 6.0  0.5 5.3  0.5*
Placebo 4.6  0.4 4.2  0.4
Chronic smokers 6.2  0.8 4.2  0.5*
Hypercholesterolemic patients 5.1  0.4 4.3  0.3*
Control subjects 4.7  0.5 5.8  0.6*
*p  0.02 versus corresponding baseline value in each study group (by the Wilcoxon
sign-rank test).
CPT  cold pressor test.
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baseline (p  NS) (Table 4). In chronic smokers, short-
term vitamin C administration (intravenous) improved
MBF responses to CPT (p  0.001) (Table 4, Figs. 2 and
3). In addition, long-term oral therapy with vitamin C led
to a sustained beneficial effect after three months and two
years of follow-up (p  0.001). The increase of MBF to
CPT in chronic smokers after intravenous vitamin C ad-
ministration was markedly stronger as compared with
MBF responses in hypertensive and hypercholesterolemic
patients (Table 4, Figs. 2 and 3) (p  0.001). In contrast,
short- and long-term vitamin C treatment did not result
in a significant CPT-induced increase in MBF in hypercho-
lesterolemic patients (p  NS) (Table 4, Fig. 2). Lastly,
high-dose vitamin C supplementation of control subjects had
virtually no effect on MBF during CPT (p  NS) (Table 4).
The group comparison of a CPT-induced increase of
MBF in hypertensive patients and chronic smokers after
three months and two years of follow-up with vitamin C
supplementation was significantly different from the placebo
and control groups (p  0.001 by ANOVA). Because
changes of CVR mirrored those of MBF for each study
group (Table 4), differences in hemodynamic responses are
unlikely to account for the observed changes in MBF during
CPT.
Correlation between responses to CPT of epicardial
coronary artery and MBF. In the overall study population
at baseline, there was a significant correlation between
percent changes in the epicardial lumen area of the proximal
artery segment and MBF during CPT (r  0.72, p 
0.0001). However, the regression analysis between the
percent changes of the lumen area of the epicardial vessel
and MBF during CPT at baseline for patients with coronary
risk factors did not show a significant correlation (r  0.34,
p  0.06; n  40). In addition, no correlation was observed
between the percent changes of the lumen area of the
epicardial artery and MBF during CPT in hypertensive
patients (r  0.07, p  0.83; n  12), placebo combined
with hypertensive group (r  0.32, p  0.17; n  20),
chronic smokers (r  0.27, p  0.45; n  10), hypercho-
lesterolemic patients (r  0.42, p  0.23; n  10), and
control subjects (r 0.51, p 0.13; n 10), except for just
the placebo group (r  0.81, p  0.015; n  8).
Table 3. Hemodynamic Responses to CPT
Group
Baseline Studies
Rest CPT
% RPPHR SBP DBP RPP HR SBP DBP RPP*
Hypertension 63  2 148  2 77  2 9,395  411 69  3 170  3 86  3 11,682  421 23  7%
Placebo 60  3 152  3 76  2 9,138  585 63  4 169  5 83  3 10,744  781 13  3%
Smokers 59  2 116  3 72  3 6,868  359 63  2 139  2 77  2 8,760  442 23  6%
Hypercholesterolemia 63  2 120  5 72  3 7,557  356 67  2 140  7 78  3 9,350  498 24  4%
Controls 56  4 136  6 74  3 7,689  509 65  5 161  9 82  3 10,431  891 40  11%
Two-Year Follow-Up After Vitamin C or Placebo
Rest CPT
% RPP‡HR SBP DBP RPP HR SBP DBP RPP†
Hypertension 65  6 149  4 78  7 9,719  1,051 70  7 170  6 84  7 11,911  988 27  4%
Placebo 62  4 154  5 79  4 9,610  995 65  5 167  7 82  5 10,890  1,409 17  3%
Smokers 60  6 117  6 69  5 7,030  924 63  6 137  7 73  5 8,644  1,426 24  2%
Hypercholesterolemia 63  4 121  4 71  3 7,623  344 67  3 141  8 79  4 9,447  523 20  3%
Controls 56  6 138  19 73  8 7,584  1,034 65  6 166  26 82  10 10,693  1,937 36  4%
*†p  0.05 CPT versus rest for each corresponding hemodynamic parameter in each study group. ‡p  NS % RPP at two-year follow-up versus % RPP at baseline studies
in each study group (Wilcoxon sign-rank test).
CPT  cold pressor test; DBP  diastolic blood pressure (mm Hg); HR  heart rate (beats/min); % RPP  percent change of RPP from rest during CPT; RPP 
rate-pressure product (systolic blood pressure  heart rate); SBP  systolic blood pressure (mm Hg).
Table 4. Mean MBF Responses and Coronary Vascular Resistance to CPT for Each Study Group
Group
Baseline Studies Two-Year Follow-Up
Rest CPT Rest CPT
MBF CVR MBF CVR MBF CVR MBF CVR
Hypertension 0.80  0.26 143  48 0.94  0.26* 131  33† 0.67  0.08 154  15 1.30  0.20* 89  12†
Placebo 0.71  0.22 150  27 0.89  0.25 134  30 0.66  0.11 161  20 0.80  0.14 145  21
Smokers 0.79  0.09 111  11 0.70  0.09 141  18 0.68  0.06 126  12 1.18  0.10 82  4
Hypercholesterolemia 0.70  0.22 136  31 0.77  0.28 138  40 0.75  0.18 126  26 0.77  0.23 142  33
Controls 0.75  0.17 134  33 1.41  0.34 78  18 0.69  0.14 140  23 1.24  0.21 90  16
*†p  0.05 versus corresponding MBF and CVR at rest in repeated assessment in each study group by the Wilcoxon sign-rank test. Mean ( SD) MBF is expressed as ml/g
per min, and mean CVR as mm Hg/ml/g per min.
CPT  cold pressor testing; CVR  coronary vascular resistance; MBF  myocardial blood flow.
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Blood chemistry. In all patients, vitamin C plasma levels
were measured before and after vitamin treatment periods of
three months and two years, respectively (Table 1). In two
patients, vitamin C plasma levels after the two years of
follow-up could not be evaluated due to blood sampling
errors. The baseline levels of vitamin C in chronic smokers
were below the normal range (0.6 to 2.0 mg/dl) and
significantly lower than in the other study groups (p 
0.05). Regular intake of 2 g vitamin C daily over the
follow-up periods resulted in a significant increase of vita-
min C concentrations in all study groups (p  0.05), apart
from the placebo group (p  NS).
Correlation between change of vitamin C levels and CBF
during CPT after two-year follow-up. Regression analysis
between the increase of vitamin C levels after the follow-up
period of two years and changes of MBF during CPT did
not reveal statistically significant correlations between the
study groups (smokers: r  0.19, p  0.65; hypertensive
patients: r  0.43, p  0.29; hypercholesterolemic patients:
r  0.57, p  0.14; and control subjects: r  0.31, p 
0.54).
DISCUSSION
The results of the present study provide several new find-
ings. At first, sympathetic activation by CPT elicits mark-
edly different vascular responses of coronary conductance
and resistance vessels, depending on cardiovascular risk
factors such as hypertension, hypercholesterolemia, and
chronic smoking. Secondly, differences in the effect of
short- and long-term vitamin C administration on abnor-
mal MBF responses in smokers and hypertensive and
hypercholesterolemic patients suggest that the mechanisms
underlying endothelial dysfunction may vary considerably.
In addition, the good reproducibility of MBF measurements
with PET may indicate that this kind of method may be
used as a tool to study the effects of pharmacologic inter-
ventions on coronary microcirculatory function.
Coronary endothelial-mediated vasoreactivity and CPT.
In the absence of significant coronary artery disease, the
endothelium-dependent responses of both epicardial con-
ductance and resistance vessels to CPT in patients with
various risk factors were significantly impaired compared
with control subjects. When looking at the study population
as a whole, there was a significant relationship between
changes in the lumen area of the large conduit vessels and
the MBF responses to CPT, which suggests that flow-
dependent changes of the epicardial lumen area correlate
well with increases in blood flow at the coronary resistance
vessel level. As reported previously (4), evaluation of coro-
nary vasomotion by CPT has demonstrated a significant
correlation between relative increases in blood flow indexes
and lumen area changes in epicardial arteries, indicating that
changes in shear stress contribute to flow-mediated vasodi-
lation in the coronary circulation. Thus, it is conceivable to
conclude that metabolic vasodilation of the coronary resis-
tance vessels due to sympathetic activation resulted in an
increase in flow throughout the vascular bed, subsequently
leading to a corresponding flow-mediated increase in epi-
cardial conductance vessel diameter (12). The different
groups at risk of coronary artery disease, such as hyperten-
Figure 2. Percent change of myocardial blood flow (MBF) during cold pressor testing (CPT) in hypercholesterolemic patients (open bars), hypertensive
patients (solid bars), and smokers (lined bars). #p  0.03 compared with baseline (CPT-1) on repeated assessments for each study group.
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sion, smoking, and hypercholesterolemia, did not demon-
strate a significant correlation between abnormal vasoreac-
tivity to CPT in conduit and arteriolar vessels, supporting
the contention that abnormal flow-mediated vasoreactivity
of epicardial coronary arteries is a different form of mani-
festation from that of the arteriolar vascular bed. These
observations are in keeping with the results of other inves-
tigators (5,6) who have shown a disparity between abnormal
endothelial-dependent epicardial and arteriolar vascular re-
sponses to acetylcholine.
MBF responses to vitamin C in patients with various risk
factors. Several investigators have previously shown that
vascular and/or endothelial dysfunction of coronary and
peripheral arterioles of chronic smokers respond well to
short-term administration of the antioxidant vitamin C
(13–15). For example, intravenous vitamin C administra-
tion improved coronary flow responses to adenosine (13).
Furthermore, Heitzer et al. (14) established a marked
enhancement of acetylcholine-induced increases in forearm
blood flow by vitamin C in chronic smokers with a history
of more than 20 pack-years. Improvement of coronary flow
responses to adenosine, however, comprises endothelium-
dependent and -independent mechanisms. Thus, the ob-
served improvement of vasodilatory dysfunction by intrave-
nous vitamin C infusion may extend previous findings to
vasomotion induced by CPT, which has been previously
shown to be largely endothelium-dependent (12,16). More
exciting, it also indicates that vasoconstriction induced by
sympathetic stimulation in chronic smokers is largely de-
pendent on the release of ROS. The precise sources of ROS,
however, remain to be determined. Several groups have
provided evidence for dysfunctional, uncoupled eNOS due
to deficiency of the NOS co-factor tetrahydrobiopterin
(BH4), since BH4 itself or its precursor sepiapterin im-
proved endothelial dysfunction in this patient population
(17). Interestingly, aggregating platelets can release large
amounts of superoxide, which may be partly due to uncou-
pled eNOS (18). As we and others have previously shown
that vitamin C has an inhibitory effect on platelet aggrega-
tion associated with an improvement of arterial vasomotion
(19,20), it is tempting to speculate that the findings ob-
served in the present study may also include beneficial effects
of vitamin C on uncoupled, dysfunctional eNOS in the
platelets of chronic smokers.
The observed beneficial effects of long-term vitamin C in
the present study are in contrast to previous findings where
regular supplementation of 1 g vitamin C daily failed to
produce a sustained beneficial effect on endothelial-
dependent vasomotion of arm vessels in smokers (21). The
reason for this discordant observation is not clear and may
be related to differences in patient characteristics, differences
in the antioxidant dose, and/or different factors determining
endothelial (dys)function in the forearm and coronary cir-
culation (22,23).
Figure 3. Changes of myocardial blood flow (MBF) during cold pressor testing (CPT) at baseline (CPT-1), after intravenous (i.v.) infusion of 3 g vitamin
C (VC) (CPT-2), and after a period of three months (CPT-3) and two years (CPT-4) of 2 g VC tablets daily in smokers. #¡p  0.001 compared with
baseline (CPT-1) on repeated assessments of changes in MBF during CPT in smokers.
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Short-term administration of vitamin C improves
endothelial-dependent vasodilation in the coronary conduit
(10) and forearm vessels (24) of hypertensive patients,
suggesting that increased vascular ROS formation contrib-
utes to endothelial dysfunction in this particular patient
population. In the present study, however, we failed to
demonstrate a beneficial effect of vitamin C on abnormal
MBF responses, indicating that other mechanisms may
contribute considerably to impaired flow-induced coronary
vasodilatory capacity in the arteriolar vascular bed. Although
we could not improve endothelial dysfunction when short-
term vitamin C was given, long-term vitamin C supplemen-
tation for three-month and two-year follow-up periods
improved abnormal MBF responses in hypertensive pa-
tients. Therefore, we speculate that the delayed onset of the
beneficial effects of vitamin C on endothelial dysfunction
may be secondary to an improvement of the redox equilib-
rium, leading to increased eNOS expression (25,26) and/or
prevention of eNOS uncoupling via enhanced bioavailabil-
ity of BH4 (27). Nevertheless, it is the first study to provide
evidence that oral treatment with vitamin C is able to
improve endothelial dysfunction of the coronary microcir-
culation in hypertensive patients.
Next, we studied endothelium-dependent responses to
short- and long-term vitamin C challenges in patients with
hypercholesterolemia. Several possible mechanism have
been proposed to account for endothelial dysfunction in this
patient group, such as selective targeting of G-protein–
dependent signal transduction by oxidized LDL, leading to
a decrease in receptor-mediated stimulation of endothelial
NO production (28). In the setting of hypercholesterolemia,
an alteration in the signal transduction cascade downstream
of NO may also be present, such as diminished sensitivity of
guanylyl cyclase (29,30), reduced Ca2 uptake via sarco/
endoplasmic reticulum Ca2 in smooth muscle cells (31).
The most attractive concept for endothelial dysfunction in
hypercholesterolemia, however, refers to increased produc-
tion of ROS (32). However, in none of our interventions
(acute short- and long-term vitamin C treatment) was a
beneficial effect of this antioxidant on CPT induced changes
in MBF observed. These negative effects are in contrast to
previous observations where single-dose vitamin C chal-
lenges (2 g), as well as long-term therapy with vitamin C
(500 mg/day) (33), improved flow-dependent dilation of the
brachial artery in patients with coronary artery disease and
may be related to different doses of vitamin C chosen for
long-term therapy and/or to the different vessel region
studied.
Conclusions. In the present study, we have established
marked differences in MBF responses to short- and long-
term vitamin C in patients with various risk factors. These
results clearly emphasize the complex nature of mechanisms
underlying abnormal coronary vasomotion. Although some
situations might implicate a predominantly abnormal redox
equilibrium between NO and ROS as a final pathway
mediating endothelial-dependent vasodilatory dysfunction,
other situations point to a defect that might locate (e.g., in
altered membrane receptor coupling) mechanisms affecting
the release of endothelial-derived NO or may involve
disturbances of the cyclic guanosine monophosphate kinase
signal transduction cascade located within smooth muscle
cells.
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